HONG KONG – A highly potent small-molecule inhibitor designed by Korean scientists has been shown both in vivo and in vitro to be a promising candidate treatment for breast cancer that preferentially targets both breast cancer stem cells (BCSCs) and bulk tumor cells, thereby potentially reducing the chances of relapse.